Figure 1From: A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian FederationNumber of subjects meeting criteria for high risk of serious RSV disease (N = 100). BPD = bronchopulmonary dysplasia; HSCHD = hemodynamically significant congenital heart disease; RSV = respiratory syncytial virus; wGA = weeks gestational age.Back to article page